TriangleAtezolizumab (NCT05312671)
Atezolizumab trial for Small Cell Neuroendocrine Carcinoma of Bladder (NCT05312671). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with localized invasive bladder cancer containing small-cell or high-grade neuroendocrine features, fit for chemotherapy, immunotherapy, and bladder-removal surgery. Metastatic disease excludes participation.
The idea: atezolizumab blocks the PD-L1 immune brake. Patients receive four three-week cycles with etoposide and either cisplatin or carboplatin, then surgery. Atezolizumab maintenance can continue for up to one year afterward. Researchers assess whether removed tissue shows no remaining cancer. Prior systemic bladder-cancer treatment is excluded.
This phase 2 study plans 63 patients. Jean Hoffman-Censits leads at Johns Hopkins, Baltimore; two US sites recruit.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.